April 28, 2021
By Miao Liu; Alvin Xu; Lin (Celine) Ming; Yinfei Wu; B. Brett Heavner
On September 4th, 2020, China’s State Administration for Market Regulation[1](the “SAMR”) released Draft Provisions on the Protection of Trade Secrets (the “Draft”) for public comments. The Draft, together with the 2019 Amendments to China’s Anti-Unfair Competition Law of the People’s Republic of China[2], sends a strong signal that China is stepping up its efforts to protect trade secrets.
Prior to the 2019 amendments, plaintiffs in Chinese trade secret cases had the burden of proving that the defendants misappropriated the plaintiffs’ trade secrets. Trade secret owners found that carrying the burden of proof in Chinese litigation to be totally impractical because the judges often rendered inconsistent decisions on what constituted trade secrets. The inconsistency confused and deterred many potential plaintiffs, because a court might require them to disclose the elements of the asserted trade secret in a court proceeding, which was more damaging than letting the defendant’s infringement continue. Furthermore, unlike the discovery process in the U.S., the Chinese civil procedural rules generally do not provide the plaintiffs with liberal discovery options such as discovery requests, depositions, expert opinions, or sanctions on the defendants who do not fulfill their discovery obligations. Thus, it was very difficult for trade secret owners to win a trade secret misappropriation claim prior to 2019. Between 2012 and 2019, Chinese district courts only granted 160 plaintiffs out of 1,737 (i.e., 9.2 %) in all trade secret claims docketed throughout the nation:
During those years, the courts dismissed 322 for insufficient pleading of a claim. 791 plaintiffs withdrew without a settlement. In 2020 alone, however, 2 out of 15 foreign trade secret owners and plaintiffs won their claims (13.3%), and only 5 withdrew with or without a settlement.
With the 2019 new draft amendments, if the trade secret owner can establish a prima facie case by providing information that reasonably indicates that the trade secret has been infringed upon, and submit any of the following evidentiary documents, the burden of proof shifts to the defendant or alleged infringer to prove the opposite:
The Article 21 of the Draft states that a trade secret owner can provide any (i.e., one or more elements) of the following information to show that it has a prima facie case to reasonably indicate that its trade secret has been infringed:
Article 24 of the Draft Provisions further states that once the trade secret owner shows that the alleged infringer has a channel or an opportunity to access the trade secret and that the information the alleged infringer uses is substantially the same as the asserted trade secret, the SAMR (and its local agencies) may issue a preliminary injunction favoring the plaintiff absent any evidence provided by the alleged infringer. For example, under the draft provisions, the following scenario could be possible: Company A sues Company B for trade secret infringement, when a prior employee of Company A responsible for product research and development joined Company B and helped B develop a product using trade secrets of A. For Company A to obtain an injunction from SAMR against B or B’s new product, it may be sufficient that A produces the employment agreement with its former employee, documents showing that the said employee had access to A’s trade secrets, and a chart outlining how A’s trade secret assets that are used in B’s new product. Together, Articles 21 and 24 of the Draft indicate that China is determined to step up on enforcement of trade secret rights. In fact, when the 2020 Draft Amendments were released, the SMAR commented that it is optimistic that these changes on the burden of proof will pass the vote at the People’s Congress. The SMAR not only intends for the Draft to provide trade secret owners with a more powerful tool to seek administrative enforcement through the SAMR and its local agencies.
Another interesting aspect of the Draft is that the SAMR has indicated, in Article 21, that it is willing to accept evidence submitted in a related legal proceeding. This provision suggests that the SAMR is willing to consolidate parallel proceedings to save plaintiffs’ time and resources, by allowing them to seek administrative enforcement while their court proceedings are still pending. Furthermore, Article 28 of the Draft Provisions gives the SAMR (and its local agencies) the power to enjoin alleged infringers from selling products manufactured using the infringed trade secrets. Accordingly, the trade secret owner can request injunctive reliefs with the SAMR through administrative proceedings (which are typically faster and less expensive compared to legal proceedings) even if the related court proceeding are still pending a final decision.
While all eyes on the final version of the Provisions on the Protection of Trade Secrets to be passed by the People’s Congress, China is determined to step up its efforts to protect trade secrets and make it less difficult for trade secret owners to prove their cases, whether it is to an administrative body or to a court. We expect trade secret owners to proactively pursue trade secret cases for which they may show a prima facie case in China.
[1]The SAMR is China’s government authority for regulating areas such as market competition, monopolies, intellectual property, and drug safety. The China National Intellectual Property Administration/Office merged into the SAMR around 2018.
[2]http://www.moj.gov.cn/news/content/2020-09/04/zlk_3255345.html
[3]Data published by Chinacourt.org at http://rmfyb.chinacourt.org/paper/html/2014-05/15/content_82072.htm.
Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.